Dermatitis

13 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Narrower: Dermatitis, Seborrheic 1, Eczema 9, Hand-Foot Syndrome 1

Treatments and conditions

Dermatitis
Treatment and conditionWhere it standsTrials
Abrocitinib for eczemaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Amlitelimab for eczemaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATI-045 for eczemaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dupilumab for dermatitisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Dupilumab for eczemaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)7
Lebrikizumab for dermatitisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lebrikizumab for eczemaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Optical Coherence Tomography + Reflectance confocal microscopy + DUPILUMAB for eczemaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for eczemaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Placebo + DUPILUMAB for eczemaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + LEBRIKIZUMAB for eczemaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Roflumilast for dermatitis, seborrheicPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
TAR-0520 gel for hand-foot syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.